Table 3 Studies suggesting that MSCs aggravate hematologic malignancy by suppressing tumor cell apoptosis in vitro
Isolated MSC | Tumor cell | Tumor cell no. (cells) | MSC:tumor cell ratio | Proposed mechanism | Reference |
|---|---|---|---|---|---|
Human BM-MSC | B-ALL (patient’s cells) | 1 × 106 | — | Secretion of soluble factors by MSCs | Manabe et al. [103] |
Human BM-MSC | CLL (patient’s cells) | 4 × 105, 2 × 106 | — | Cell-to-cell contact of tumor cells with MSCs | Panayiotidis et al. [104] |
Human BM-MSC | B-CLL (patient’s cells) | 2 × 106 | — | Increased Bcl-2 expression by direct contact between leukemic cells and stromal cells | Lagneaux et al. [105] |
Human BM-MSC | B-ALL (patient’s cells) | 1 × 105 | 1:10 | Activation of Notch-3 and -4 signaling when tumor cells are in contact with MSCs | Nwabo Kamdje et al. [106] |
Human stromal cell line (HS-5) | AML (patient’s cells) | 4–6 × 105 | 1:4~1:6 | Direct cell-to-cell interactions regulating antiapoptotic effects, not including Bcl-2 | Garrido et al. [107] |
Mouse stromal cell line (MS-5) | AML (HL-60 and patient’s cells) | 5 × 105 | — | Increased Bcl-2 expression | Konopleva et al. [108] |
Human BM-MSC | BCP-ALL (patient’s cells) | — | — | Secretion of PGE2 from MSCs | Naderi et al. [109] |
Leukemia patient’s BM-MSC | CML (K562) | 1 × 105 | 1:10 | Activation of the PI3K-Akt-Bad pathway | Wei et al. [34] |
Human UC-MSC | T-ALL (Jurkat) | 2 × 106 | 1:10 | Activation of the Notch signaling pathway | Yuan et al. [76] |
Human BM-MSC | CML (BV173) | 1 × 106 | 1:10 | Transient cell cycle arrest conferring increased leukemic cell survival by preserving their proliferative ability | Ramasamy et al. [23] |
